High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial

BACKGROUND: High-dose rifampicin may improve outcomes of tuberculous meningitis (TBM). Little safety or pharmacokinetic (PK) data exist on high-dose rifampicin in human immunodeficiency virus (HIV) coinfection, and no cerebrospinal fluid (CSF) PK data exist from Africa. We hypothesized that high-dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Cresswell, Fiona V, Meya, David B, Kagimu, Enock, Grint, Daniel, te Brake, Lindsey, Kasibante, John, Martyn, Emily, Rutakingirwa, Morris, Quinn, Carson M, Okirwoth, Micheal, Tugume, Lillian, Ssembambulidde, Kenneth, Musubire, Abdu K, Bangdiwala, Ananta S, Buzibye, Allan, Muzoora, Conrad, Svensson, Elin M, Aarnoutse, Rob, Boulware, David R, Elliott, Alison M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423465/
https://www.ncbi.nlm.nih.gov/pubmed/33693537
http://dx.doi.org/10.1093/cid/ciab162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423465/
https://www.ncbi.nlm.nih.gov/pubmed/33693537
http://dx.doi.org/10.1093/cid/ciab162

Ejemplares similares